Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03557424
Other study ID # BEFORE-Study
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 26, 2017
Est. completion date April 16, 2018

Study information

Verified date June 2018
Source Heilpflanzenwohl AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The BEFORE study ((B) EFficacy Of REfigura) is designed to demonstrate the efficacy of REFIGURA®. It is a double-blind, randomized, monocentric study.


Description:

Core data from the BEFORE study:

Sponsor: Heilpflanzenwohl AG Product: REFIGURA® Title: BEFORE study: Demonstrating the efficacy of REFIGURA® through a double-blind, three-arm, randomized, monocentric study Study duration: 8 weeks (56 days) Study location: MIT Gesundheit GmbH, Stechbahn 20-22, 47533 Kleve CRO: MIT Health GmbH, Stechbahn 20-22, 47533 Kleve Number of study participants: 165 (55 patients per treatment arm)

Summary:

REFIGURA® (manufactured by KITOZYME, Parc Industriel des Hauts-Sarts, Zone 2, Rue de Milmort, 680, BE-4040 Herstal, Belgium, Distribution: Heilpflanzenwohlkraft GmbH), is an approved medical device containing a combination of chitosan (a polyglucosamine ) and glucomannan. Chitosan is a vegetable fiber that binds fats in the intestinal lumen. Both substances are already approved and show few side effects. They are not absorbed into the body, but work directly in the intestine.

The investigational medicinal products are used to treat obesity (weight loss) and to control weight. The effect is based on a reduction in caloric intake, by increasing the feeling of satiety and at the same time the appetite is reduced. As a result, the amount of food consumed is reduced and excessive food (cravings attacks) is prevented. It also reduces the intake of dietary fats.

The study compares three treatment arms:

1. placebo

2. Verum (in the normal, approved dose)

3. Verum (in the double dose)

The patients are weighed, their body fat content is measured and the body size is measured. All measurement methods are non-invasive.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date April 16, 2018
Est. primary completion date April 16, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:

- Age 20-50 years

- Body mass index (BMI) = 30 kg/m² or

- BMI between 25 and ? 30 kg/m² and simultaneous existence of at least one of the following factors:

1. Overweight-related health disorder (e.g. Hypertension, type 2 Diabetes m.)

2. Abdominal Obesity

3. A disease aggravated by obesity

4. High psychosocial pressure of suffering

Exclusion Criteria:

- Pregnancy (examination with the help of a pregnancy test using urine Lab Test at V2) and lactation

- Alcohol, drugs and drug abuse

- Limited compliance (pre-questionnaire examination)

- History of malignant tumors

- (chronic) Inflammatory diseases of the gastrointestinal tract

- Gastroparesis (stomach paralysis) in the anamnesis

- Signs of an intestinal closure (arising or existing mechanical or paralytic Ileus) in the anamnesis

- Gastric bridging surgery or gastric reduction

- Hypersensitivity or allergy to the ingredients

- Untreated or inadequately treated hypertension

- Diabetes mellitus (examination with the help of a urine tests)

- Treatment with diuretics or insulin

- Cortisone, which has a systemic effect

- Smokers who want to start weaning during the trial

- Untreated or insufficiently treated thyriodale disorders (if the patient is stable in the opinion of the physician, he may participate in the study)

- Cardiac edema

- Participation in weight reduction programs in the past 30 days

- Patients with swallowing problems, intestinal polyps or severe digestive disorders

- Patients with a history of constipation

- Patients who take drugs containing fat-soluble active substances and in which the time-consuming conditions of these drugs (see instructions for taking in Appendix O) are incompatible with the intake instructions of this study.

Study Design


Intervention

Drug:
Polyglucosamine Glucomannan normal dose (Verum)
Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Polyglucosamine Glucomannan high dose (Verum)
Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Placebo Comparator: Placebo
Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.

Locations

Country Name City State
Germany MIT Gesundheit GmbH Kleve NRW

Sponsors (1)

Lead Sponsor Collaborator
Heilpflanzenwohl AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Bodyweight Changes in bodyweight during the study (weight reduction in kg). Comparison of the values obtained on day1 with results from day 65. Every two weeks (Start, 2 weeks, 4 weeks, 6 weeks, 8 Weeks)
Secondary Changes in BMI Changes in body-mass-index during the study. Comparison of the values obtained on day1 with results from day 65. Every two weeks (Start, 2 weeks, 4 weeks, 6 weeks, 8 Weeks)
Secondary Safety: occurence of adverse events Explore the occurence of adverse Events in the three different arms. Every week (from week 1 to week 10)
Secondary Changes in blood pressure Changes in blood pressure values during the study. Comparison of the values obtained on day1 with results from day 65. Every two weeks (Start, 2 weeks, 4 weeks, 6 weeks, 8 Weeks)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A